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Abstract
To elucidate the molecular mechanisms underlying non-alcoholic
fatty liver disease (NAFLD), we recruited 86 subjects with varying
degrees of hepatic steatosis (HS). We obtained experimental data
on lipoprotein fluxes and used these individual measurements as
personalized constraints of a hepatocyte genome-scale metabolic
model to investigate metabolic differences in liver, taking into
account its interactions with other tissues. Our systems level anal-
ysis predicted an altered demand for NAD+ and glutathione (GSH)
in subjects with high HS. Our analysis and metabolomic measure-
ments showed that plasma levels of glycine, serine, and associated
metabolites are negatively correlated with HS, suggesting that
these GSH metabolism precursors might be limiting. Quantification
of the hepatic expression levels of the associated enzymes further
pointed to altered de novo GSH synthesis. To assess the effect of
GSH and NAD+ repletion on the development of NAFLD, we added
precursors for GSH and NAD+ biosynthesis to the Western diet and
demonstrated that supplementation prevents HS in mice. In a
proof-of-concept human study, we found improved liver function
and decreased HS after supplementation with serine (a precursor
to glycine) and hereby propose a strategy for NAFLD treatment.
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Introduction
Hepatic steatosis (HS) is defined as the accumulation of fat in liver
with no evidence of hepatocellular injury, and it is the most
common chronic liver disease worldwide (Vetelainen et al, 2007).
HS is the characteristic feature of non-alcoholic fatty liver disease
(NAFLD) and it is strongly associated with obesity, insulin resis-
tance, type 2 diabetes (T2D), and cardiovascular diseases (Ratziu
et al, 2010). Up to 30% of subjects with NAFLD develop non-
alcoholic steatohepatitis (NASH) which is a serious illness in which
inflammation and scarring eventually can lead to cirrhosis and
hepatocellular carcinoma (HCC) (Dyson et al, 2014).
The underlying molecular mechanisms leading to the occurrence
of HS and its transition to severe liver disorders remain elusive,
which limits the identification of drug targets and discovery of
biomarkers that may be used to design effective treatment strategies.
There are currently few pharmaceutical treatments for HS and its
associated clinical conditions (Machado & Cortez-Pinto, 2012), and
an integrative systems biology-based approach may help to address
these significant unmet medical needs. In this context, genome-scale
metabolic models (GEMs) can be used to gain more insights about
the molecular mechanisms involved in the occurrence of HS and
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associated disorders, and in turn may enable future therapeutic
discoveries (Mardinoglu & Nielsen, 2012, 2015; Yizhak et al, 2013,
2014a,b; Zhang et al, 2015). GEMs are the collection of biochemical
reactions that are known to occur in particular cells/tissues, and
these models have been used in the integration of cellular, physiolog-
ical, and clinical data to reveal the underlying molecular mecha-
nisms of metabolism-related disorders (Folger et al, 2011; Frezza
et al, 2011; Mardinoglu et al, 2013a,b, 2014b, 2015a; Agren et al,
2014; Ghaffari et al, 2015; Varemo et al, 2015; Lee et al, 2016a,b).
We have previously reconstructed a GEM for hepatocytes (iHepato-
cytes2322) and used it to analyze transcriptomics data obtained from
NAFLD patients (Mardinoglu et al, 2014a). In addition, a GEM study
showed that the liver adaptively regulates metabolic responses to
maintain its basic functions and that NAFLD is associated with
increased glyceroneogenesis and a switch from lactate to glycerol as
a substrate for gluconeogenesis (Hyo¨tyla¨inen et al, 2016).
To design effective treatment strategies for NAFLD, it is also
necessary to understand the pathophysiology of dyslipidemia. Tradi-
tional approaches that measure plasma concentrations of lipopro-
teins provide only static estimates with limited mechanistic
information. As an alternative, tracers labeled with stable isotopes
can be used as a powerful tool for probing lipid and lipoprotein
kinetics in vivo to provide an increased understanding about the
pathogenesis of dyslipidemia (Boren et al, 2012; Adiels et al, 2015).
The GEM iHepatocytes2322 contains extensive information about
lipid metabolism (Mardinoglu et al, 2014a), which is necessary for
studying the effect of excess amount of lipids on the underlying
molecular mechanism of NAFLD. This GEM can thus be used as a
platform for studying the kinetics of lipoproteins and their potential
effect on liver metabolism.
To clarify the underlying metabolic disturbances in NAFLD, we
investigated the metabolic differences in liver between subjects with
varying degrees of HS by studying the kinetics of lipid metabolism,
taking into account interactions between the liver, adipose, muscle,
and other peripheral tissues as well as red blood cells. Using person-
alized genome-scale metabolic modeling, we elucidated an under-
lying molecular mechanism of NAFLD which can be used in the
development of an effective treatment strategy.
Results
Characteristics of subjects with varying degrees of HS
We recruited 86 subjects (75 men and 11 women; Fig 1A) and deter-
mined the liver fat content of each subject using magnetic resonance
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Figure 1. Generation of VLDL kinetics and plasma metabolomics data.
A To identify the metabolic changes in response to increased hepatic steatosis (HS), secretion rate of the VLDLs from the liver of subjects was measured and the plasma
metabolite levels were detected in subjects with varying degrees of HS.
B BMI, insulin resistance (HOMA-IR), plasma TGs, and ALT levels are significantly correlated with the independently measured liver fat.
C The subjects were categorized into two groups as high (n = 43) and low HS (n = 43). Body mass index (BMI), fasting plasma insulin (FPI), plasma triglycerides (TGs), and
plasma alanine aminotransferase (ALT) levels are found to be significantly different between the two groups. Data are presented as means  SD. *P < 0.05; Student’s t-test.
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spectroscopy (Adiels et al, 2006; Lundbom et al, 2011). The clinical
characteristics of all the subjects involved in the study are presented
in Table 1. We calculated the Pearson correlation coefficient (r)
between HS and other clinical parameters and found that HS was
significantly (P < 0.05) positively correlated with weight, body mass
index (BMI), insulin resistance (HOMA-IR), plasma triglyceride
(TG), and the liver enzyme alanine aminotransferase (ALT) levels
(Fig 1B). The ratio of ALT to aspartate transaminase (AST) also
significantly (P < 0.05) correlated (r = 0.57) with HS. None of the
other liver-related clinical parameters (AST, alkaline phosphatase
(ALP), and c-glutamyl transferase (GT)), blood lipid-related parame-
ters (high-density lipoprotein (HDL) cholesterol, total cholesterol,
and apolipoprotein B (apoB)) nor the inflammation marker C-
reactive protein (CRP) correlated significantly with HS.
We classified the subjects with varying degrees of HS into two
groups of 43 subjects based on their liver fat percentage: high HS
(> 5.5%) and low HS (< 5.5%) (Table 1). We found that subjects
with high HS were significantly (P < 0.05) heavier with a greater
BMI. Fasting plasma glucose and fasting plasma insulin (FPI)
concentrations were significantly (P < 0.05) higher in subjects
with high HS compared to subjects with low HS (Fig 1C). The
average plasma TG concentration was 2.05 and 1.67 mmol/l for
subjects with high and low HS, respectively (Fig 1C). We did not
detect any significant plasma differences in other lipid parameters
including apoB, HDL cholesterol, and total cholesterol (Table 1).
The ALT level was significantly higher in subjects with high HS
(Fig 1C). In summary, the average subject with low HS involved
in our study was overweight, borderline hypertriglyceridemic but
insulin sensitive, whereas the average subject with high HS
was obese, hypertriglyceridemic and insulin resistant but did not
have T2D.
Personalized liver tissue GEMs
To elucidate the underlying molecular mechanisms of HS, we
adopted constraint-based modeling techniques to identify major
hepatic metabolic alterations between subjects with varying degrees
of HS. The secretion rates of non-esterified fatty acids (FAs) and
amino acids (AAs) from adipose and muscle tissues were calculated
based on the body composition of each subject and used as input to
the personalized liver GEMs together with the lactate secreted by
red blood cells (Fig 2A and Materials and Methods, and Dataset
EV1). Since the level of TG-rich very-low-density lipoproteins
(VLDLs) is the major determinant of plasma TG, we combined
kinetic studies with stable isotopes and multicompartment modeling
to infer the parameters of VLDL kinetics in 73 of the subjects (65
men and 8 women) involved in our study. We observed a significant
correlation between secreted VLDL and HS (r = 0.581, P < 0.001)
and used secretion rate of VLDL as an objective function for the
personalized liver GEMs (Dataset EV1).
We simulated the dynamics of the liver metabolism that would
ideally correspond to the increased HS using the inputs and outputs
to the liver as constraints of personalized GEMs. We predicted the
intracellular fluxes in the liver of each subject (Dataset EV2) and
calculated the Pearson correlation coefficient between the intracellu-
lar fluxes and HS of each subject (Dataset EV3). We found that reac-
tions involved in protein synthesis had the highest correlations with
HS (r = 0.57, P < 0.001). We also quantified the apoB content in the
total VLDL produced by the liver and found that it correlated signifi-
cantly with the measured HS (r = 0.581, P < 0.001) (Fig 2B). This
correlation was very similar to that observed between the TG
content in the total VLDL produced and the measured HS
(r = 0.576, P < 0.001) (Fig 2C). Hence, we observed that
Table 1. Clinical characteristics of the 86 study participants.
Characteristic
Low HS
HS (%) < 5.5
n = 43
High HS
HS (%) > 5.5
n = 43 P-value
Liver fat (%) 2.8  1.7 13.4  6.4 <0.05
Age (years) 52.1  8.4 52.6  8.0 0.76
Weight (kg) 92.4  11.2 102.2  14.0 <0.05
Body mass index (BMI) (kg/m²) 29.7  3.2 32.9  3.4 <0.05
Fasting plasma glucose (mmol/l) 5.5  0.5 5.85  0.6 <0.05
Fasting plasma insulin (FPI) (mU/l) 7.6  5.0 14.0  7.0 <0.05
HOMA-IR 1.9  1.3 3.7  2.0 <0.05
C-reactive protein (CRP) (mg/l) 2.4  2.8 3.3  3.3 0.31
Plasma triglycerides (TG) (mmol/l) 1.7  0.6 2.1  0.8 <0.05
Apolipoprotein B (apoB) (mg/dl) 90.2  29.0 97.4  30.7 0.30
Total cholesterol (mmol/l) 4.9  0.85 5.1  0.7 0.31
HDL cholesterol (mmol/l) 1.1  0.3 1.1  0.3 0.96
Alanine aminotransferase (ALT) (U/l) 23.5  9.3 38.9  28.3 <0.05
Aspartate aminotransferase (AST) (U/l) 21.9  5.1 23.2  5.8 0.41
Alkaline phosphatase (ALP) (U/l) 63.2  16.7 70.5  19.3 0.16
c-glutamyl transferase (GT) (U/l) 27.6  16.4 31.2  13.9 0.40
Data are presented as means  SD. P-value indicates significance level of difference between the subjects with low and high hepatic steatosis (HS). P-values
were calculated using Student’s t-test. Bold text indicate significantly different values.
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personalized GEMs were able to predict the response of liver to the
increased HS.
Reactions with the second and third highest correlations with
HS were those involved in the reduction of H2O2 (r = 0.482,
P < 0.001) and those associated with nicotinamide nucleotide trans-
hydrogenase (NNT) (r = 0.479, P < 0.001), respectively. NNT cata-
lyzes the interconversion of NADH and NADP+ to NAD+ and
NADPH in the mitochondria. NNT has an important role in provid-
ing NAD+ for fat oxidation as well as NADPH for redox detoxifi-
cation since NADPH is used for the regeneration of glutathione
(GSH) through reduction of glutathione disulfide (GSSG), which is
catalyzed by glutathione reductase (GSR) (Fig 2D). Notably, we
found that the flux carried by the reaction associated with GSR was
one of those with the highest correlations with HS (r = 0.478,
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Figure 2. Personalized modeling of liver in subjects with varying degrees of HS.
A Schematic illustration of how personalized genome-scale metabolic modeling can be performed accounting the interactions between other tissues and red blood
cells for the development of effective therapeutic approaches for non-alcoholic fatty liver disease (NAFLD). Solid and dashed arrows show the outputs and inputs to
the tissues, respectively.
B, C The correlation between the predicted intracellular fluxes of the liver and hepatic steatosis (HS) is assessed and compared with the (B) apolipoprotein B (apoB) and
(C) triglycerides (TG) content in the total VLDL production.
D The fluxes carried by the reactions catalyzed by NNT, GSR, and GPXs are found to be the most correlated reactions with the HS (Dataset EV3). Green arrow
indicates the significant correlation of the flux carried by the reactions and HS.
E The net fat influx (NFI) is calculated as the differences in the uptake and secretion rates of FAs and its correlation with the intracellular fluxes are assessed.
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P < 0.001). Moreover, we found that reactions involved in fat
oxidation significantly correlated with HS (r = 0.477, P < 0.001)
(Dataset EV3). Increases in the flux carried by the reactions cata-
lyzed by NNT and GSR would generate additional NAD+, which is
necessary for the increased fat oxidation and GSH, which is neces-
sary to scavenge excessively produced reactive oxygen species
resulting from increased fat oxidation. It has previously been
reported that NNT is essential for normal cellular metabolism and
for mitochondrial defense against oxidative stress (Huang et al,
2006). In addition, we observed a significant correlation between
HS and secreted ketone bodies, which are one of the major outputs
of the liver GEM (r = 0.475, P < 0.001) (Dataset EV3).
Hepatic steatosis results from an imbalance between the
de novo synthesis, oxidation, uptake, and export of FAs (Tamura &
Shimomura, 2005). Hence, we calculated the differences in the
uptake and secretion rates of FAs, defined as net fat influx (NFI)
(Fig 2E), in the liver of each subject, and calculated the correlations
between the intracellular fluxes and NFI (Dataset EV4). Notably, we
found that the reactions catalyzed by GSR (r = 0.812, P < 0.001)
and NNT (r = 0.811, P < 0.001) had the highest correlations with
NFI. We also found that the reaction catalyzed by glutathione
peroxidases (GPXs) and peroxiredoxins (PRDXs) (Fig 2D), which
detoxify peroxides and hydroperoxides, was significantly correlated
with NFI (r = 0.812, P < 0.001) (Dataset EV4). In addition, we
observed a significant correlation between NFI and secreted ketone
bodies (r = 0.782, P < 0.001).
Increased GSH and NAD+ formation as well as the increased fat
oxidation in our in silico analysis are model-predicted demands
which would ideally be met for dealing with high HS. If these
demands cannot easily be met in vivo due to reduced concentrations
of the substrates, then cellular health might be compromised.
Considering that our simulations demonstrated the ideal response of
the liver to the increased HS, the upregulation of the fat oxidation as
well as the increased availability of the GSH and NAD+ may provide
potential treatment strategy for NAFLD subjects.
Glycine is the limiting substrate for de novo synthesis of GSH
in NAFLD
Depletion of GSH can lead to mitochondrial dysfunction and cell
death (Fernandez-Checa & Kaplowitz, 2005; Garcia-Canaveras et al,
2011). Based on our in silico analysis, we proposed that an
increased expression of NNT would be needed to boost the level of
NAD+ to respond to the increased fat oxidation whereas NNT and
GSR may boost the level of GSH required for resisting oxidative
stress and maintaining the reducing environment of the liver.
However, if the expression of NNT and GSR cannot meet this
demand or even decrease in the pathological state, it may result in
depletion of NAD+ and GSH and eventually to accumulation of fat
in the liver. Indeed, hepatic depletion of NAD+ in mice model of
NAFLD has been reported (Gariani et al, 2016; Zhou et al, 2016).
Moreover, lower concentrations of both GSH and GSSG and a reduc-
tion in the GSH/GSSG ratio have been reported in the liver (Garcia-
Canaveras et al, 2011) and serum (Kalhan et al, 2011) of NAFLD
patients compared to healthy subjects.
Depleted GSH can also be replaced by de novo synthesis of GSH
from glutamine, glycine, and cysteine which can be taken up from
the plasma. To detect the plasma level of these AAs, we performed
non-targeted metabolomics profiling in plasma from 86 subjects and
analyzed levels of ~520 metabolites. We assessed the correlations
between the plasma metabolite levels and HS (Dataset EV5). Fasting
plasma levels of glycine and N-acetylglycine as well as betaine and
serine (which can be converted to glycine) showed significantly
negative correlations with HS (Fig 3A). We also assessed the corre-
lation coefficients between the plasma metabolites that correlated
significantly with HS (Fig 3B) and found that plasma glycine levels
showed the highest correlation with the plasma serine levels among
all other measured metabolites (r = 0.77, P < 0.05) (Dataset EV5). It
should be noted that we did not detect any significant correlation
between HS and the plasma levels of cysteine and glutamine (which
are also required for the de novo synthesis of GSH).
We also investigated whether any of the plasma metabolites
showed significant differences between the two groups of subjects
divided according to their level of HS (Dataset EV6). We found that
the levels of glycine, serine, betaine, and N-acetylglycine were
significantly (Welsh’s t-test, P < 0.05) lower in subjects with high
HS compared to those with low HS (Fig 4). In addition to the
metabolites associated with glycine, we also found that the levels of
butyrylcarnitine, glycylphenylalanine, gamma-tocopherol (vitamin
E), kynurenate, N-delta-acetylornithine, N-methyl proline, and a
number of lipid structures, which have been shown to correlate
with HS in Fig 3 were significantly changed (Welsh’s t-test,
P < 0.05) between the subjects with high and low HS (Fig 4).
Changes in the plasma levels of butyrylcarnitine, glycine as well as
some of other metabolites identified in our study have previously
been observed in studies that compared NAFLD subjects to healthy
subjects (Kalhan et al, 2011; Dumas et al, 2014).
Decreased expression of the enzymes involved in GSH formation
We revealed that a disturbed redox balance (i.e., NAD+ and GSH
deficiency) was linked to metabolic dysfunction and development of
NAFLD. In this context, we measured the expression of NNT, GSR,
and the enzymes involved in the de novo GSH synthesis in human
liver samples obtained from a separate cohort of 12 obese subjects
with high HS who underwent bariatric surgery (Table 2) and
compared with the expression of the genes in liver samples obtained
from seven healthy individuals (previously described in Uhlen et al,
2015) (Fig 5A). We found that mRNA expression of NNT, GSR, and
the rate-limiting enzymes in de novo GSH synthesis, namely gluta-
mate–cysteine ligase, catalytic subunit (GCLC) and glutamate–
cysteine ligase, modifier subunit (GCLM), were significantly lower in
liver from obese subjects than from healthy subjects (Fig 5B–E). This
indicated that the decreased expression of the NNT and GSR may
lead to increased HS which is in agreement with the results of
personalized modeling of subjects with varying degree of HS.
Supplementation of GSH and NAD+ precursors decreases HS
in mice
Our analysis indicated depletion of the NAD+ and GSH in subjects
with high HS. It has been shown that supplementation of natural
NAD+ precursors, such as tryptophan, nicotinamide riboside (NR),
niacin, and nicotinamide, elevates NAD+ levels in vivo (Houtkooper
et al, 2010; Canto et al, 2012). The plasma and liver level of GSH is
depleted in NAFLD patients and cannot be increased by
ª 2017 The Authors Molecular Systems Biology 13: 916 | 2017
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supplementation with GSH; instead, GSH must be synthesized
within the liver either de novo or by the salvation pathway. Our
analysis suggested that the level of GSH is not sufficient to maintain
and regulate the thiol-redox status of the liver in subjects with high
HS in the fasting state due to the depletion of glycine. Glycine can
be synthesized via the interconversion of serine through serine
hydroxymethyltransferases with concomitant conversion of tetra-
hydrofolate (THF) into 5,10-methylene-THF (Fig 5A). During the
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conversion of serine to glycine, an additional carbon unit is
provided for one-carbon metabolism. Previously, we have shown
that serine synthesis is downregulated in NASH patients (Mardi-
noglu et al, 2014a). Taken together, we therefore hypothesized that
dietary supplementation with NR may increase the level of NAD+
required for the increased fat oxidation and serine may increase the
level of glycine and the level of GSH (by intracellular GSH synthesis
from glycine). Supplementation of the substrates for NAD+ and
GSH may increase the amount of the fat oxidized in the liver, lower
oxidative stress resulting from high fat oxidation, lower the level of
HS, and eventually improve liver function.
To assess the effect of GSH and NAD+ repletion on the develop-
ment of HS in mice, we supplemented a cocktail consisting of
serine, NAC (N-acetyl-L-cysteine), and NR to mice fed with Western
diet, including high levels of fat and sucrose. Serine was included
into the cocktail since it can be easily converted to glycine whereas
NAC was included since cysteine may be the limiting metabolite
after the repletion of the glycine in the synthesis of GSH. NR was
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Figure 4. Identification of significantly changed metabolites in subjects with high HS.
The plasma level of ~520metabolites was detected by untargeted metabolomics profiling and significantly (P < 0.05) changed metabolites are presented using volcano plot.
Metabolites that can be converted to glycine marked bold.
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included in the cocktail to increase the amount of NAD+ in the
liver. We treated Western diet-fed male C57BL/6J mice with serine
(300 mg/kg/day) and NR (400 mg/kg/day) la gavage as well as
NAC (1g/l) in the drinking water for 14 days and sacrificed the mice
4 h after the last treatment. We obtained liver tissue samples from
the mice, performed liver lipidomics analysis and observed 50%
reduction in hepatic TGs (Fig 6A), tendency to decrease in the level
of cholesterol esters (Fig 6B) and ceramides (Fig 6C), and tendency
to increase in the level sphingomyelin (Fig 6D) and no significant
changes in the level of phosphatidylethanolamine (Fig 6E). We also
measured the level of glycine and serine and found that their plasma
level was significantly increased after supplementation of the cock-
tail (Fig 6F). We finally measured the liver level of TGs with dif-
ferent chain lengths and found that shorter chain lengths of TGs
that are preferentially oxidized in the mitochondria were signifi-
cantly decreased after supplementation (Fig 6G). Hence, we demon-
strated that supplementation of the metabolites that are predicted by
personalized modeling promotes the oxidation of fat in the liver,
prevents HS, and hereby proposed a therapeutic strategy for protect-
ing against NAFLD progression.
Fat oxidation and fatty acid synthesis are reciprocal metabolic
pathways (Foster, 2012). In order to check whether the de novo lipo-
genesis is inhibited by the supplementation of the cocktail, we
measured the expression of the fatty acid synthase (Fasn), a key
enzyme involved in the de novo lipogenesis in the liver tissue of the
mice but did not find any significant differences in its expression
before and after the supplementation of the cocktail (Fig 6H).
Supplementation of serine decreases HS in humans
To identify the unique contribution of serine supplementation in
decreasing HS, we assessed the effect of short-term dietary supple-
mentation with serine on HS and fasting levels of plasma markers of
liver functions in six subjects with high HS. Characteristics of the
six subjects before and after the supplementation are presented in
Table 3. Each patient received one oral dose of ~20 g of L-serine
(200 mg/kg/day) for 14 days. The supplementation was well
tolerated by all the subjects. We found that plasma ALT, AST, and
ALP levels were significantly decreased after supplementation
(Table 3). Notably, we found that the plasma levels of ALT (Fig 6I)
and AST (Fig 6J) were consistently decreased in all six subjects and
ALP was decreased in five of the participating subjects (Fig 6K).
Moreover, we found that the plasma TGs were decreased in five of
the studied subjects and did not change in the remaining one subject
(Fig 6L). We finally measured the HS using magnetic resonance
spectroscopy before and after serine supplementation and demon-
strated that HS is significantly decreased after serine supplementa-
tion (Table 3). HS is decreased in all six patients, and the relative
decrease in NAFLD patients ranged between 1.0 and 23%.
Discussion
Personalized genome-scale metabolic modeling provides deeper
insight into clinical data, enabling increased understanding of the
genotype–phenotype relationship. We characterized subjects with
varying degrees of HS and measured VLDL kinetics. Subsequently,
we integrated the VLDL kinetic data with additional experimentally
derived flux data to simulate the desired dynamics of liver metabo-
lism of each subject using a liver GEM. We then assessed the correla-
tions between the predicted intracellular fluxes of the liver and HS to
investigate whether any metabolic derangements could be detected
in NAFLD. Our systems level analysis indicated that altered NAD+
and GSH metabolism (with increased demand for NAD+ and GSH in
NAFLD) was a prevailing feature in NAFLD. Hence, we postulated
that subjects with NAFLD have reduced de novo synthesis of GSH,
possibly due to limited availability of glycine in the fasting state. We
analyzed plasma metabolomics and showed that plasma levels of
glycine as well as serine, betaine, and N-acetylglycine (which can be
converted to glycine) were lower in subjects with high HS compared
to those with low HS. Moreover, analysis of the metabolomics data
revealed significant negative correlations between the plasma levels
of glycine, serine, betaine, and N-acetylglycine with HS. In a mice
study, we showed that supplementation of the precursors for NAD+
and GSH significantly decreased HS. Finally, in a proof-of-concept
human study, we found that HS is significantly decreased whereas
markers of liver function are significantly improved in NAFLD
patients after supplementation with serine (a precursor to glycine).
Our finding highlighting the importance of glycine is consistent
with an earlier pilot study which showed that supplementation with
betaine (which is degraded to sarcosine and glycine) resulted in
significant biochemical and histological improvements in patients
with NASH (Abdelmalek et al, 2001). Furthermore, mice deficient
in glycine N-methyltransferase (Gnmt), which is involved in the
degradation of betaine to glycine, have hyperlipidemia and steato-
hepatitis (Liao et al, 2012). In addition, glycine supplementation to
rats with alcohol-induced liver injury has been shown to protect
against free radical-mediated oxidative stress in hepatocytes
(Senthilkumar et al, 2004).
Serine derived from a branch of glycolysis can be converted to
glycine, which in turn provides carbon units for one-carbon metabo-
lism using THF. It has been shown that NAFLD patients and
controls have similar folate levels (de Carvalho et al, 2013), and
THF is therefore not likely to be limiting for glycine biosynthesis. In
this context, serine supplementation to mice and rats has been
Table 2. Clinical characteristics of the twelve obese subjects who
underwent bariatric surgery with high HS.
Clinical variable
Obese subjects with
high HS (n = 12)
Age (years) 39.3  10.9
Weight (kg) 122.9  12.8
Body mass index (BMI) (kg/m²) 43.6  3.6
Fasting plasma glucose (mmol/l) 5.6  0.6
Fasting plasma insulin (FPI) (pmol/l) 128.7  49.9
HOMA-IR 4.7  1.9
Plasma triglycerides (TG) (mmol/l) 1.5  0.5
Total cholesterol (mmol/l) 5.1  0.7
LDL cholesterol (mmol/l) 3.1  0.7
HDL cholesterol (mmol/l) 1.3  0.3
Alanine aminotransferase (ALT) (U/l) 25.3  16.3
c-glutamyl transferase (GT) (U/l) 30.7  23.2
Data are presented as means  SD.
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shown to attenuate alcoholic fatty liver by enhancing homocysteine
metabolism (Sim et al, 2015).
Increased release of free FAs in the fasting state is a known char-
acteristic of obesity and associated disorders such as NAFLD
(Nestel & Whyte, 1968; Karpe et al, 2011). We showed that the
influx of FAs into the liver with simultaneous low secretion of
VLDL (i.e., high NFI) profoundly affected the fluxes. GSH turnover
as well as increased fat oxidation, increased oxidative phosphoryla-
tion with subsequent increased demand for oxygen, and increased
ketogenesis were strongly correlated with high NFI. However, it
should be noted that although the flux of the reactions involved in
these pathways were able to increase in response to increased
demand according to our in silico model, this might not be the case
in vivo. Hence, the increases in GSH, NAD+, fat oxidation, oxygen
consumption, and ketone production are thus all model-predicted
demands which would ideally be met for dealing with high HS. For
example, if the predicted demand for GSH in high HS is not met by
an increased supply of GSH, then the redox balance could be at risk
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Figure 5. Glycine is the limiting substrate in the synthesis of GSH in NAFLD.
A Glycine is found to be the limiting substrate for the synthesis of glutathione (GSH) in subjects with NAFLD. Decreased de novo synthesis of serine has also been
reported in subjects with NASH. The decreased plasma level of glycine, serine as well as other associated metabolites betaine and N-acetylglycine in subjects with
high HS is confirmed with the metabolomics study. In order to confirm model-based predictions, serine was supplemented to the subjects with high HS since serine-
derived carbon can be converted to GSH to satisfy the increased demand for GSH in NAFLD. Blue arrows indicated downregulation whereas the red arrow indicates
upregulation of the reactions. Green arrows indicate the significant correlation of the flux carried by the reactions and HS. [c], cytoplasm; [m], mitochondria.
B–E The mRNA expressions of the (B) nicotinamide nucleotide transhydrogenase (NNT), (C) glutathione reductase (GSR), (D) glutamate–cysteine ligase, catalytic subunit
(GCLC), and (E) glutamate–cysteine ligase, modifier subunit (GCLM) are measured in the livers obtained from 12 morbidly obese subjects who had undergone
bariatric surgery and seven healthy individuals (mean  SD). *P < 0.05; Student’s t-test.
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of being insufficient for normal cellular health in high HS. Indeed,
we showed the mRNA expression of the enzymes involved in the
formation of GSH is significantly lower in obese subjects.
The subjects at highest risk of possible metabolic stress in this
analysis were subjects with high FA influx and HS. Importantly, HS
alone was not the single characteristic that explained higher demand
for GSH, meaning a person with high HS is not necessarily at risk.
Since metabolic distress was predicted to correlate well with high
NFI and FA influx alone, it can therefore be argued that a subject
with high HS but low FA influx is not necessarily at risk of disease.
In fact, the expansion of intracellular stored lipids in the liver is one
way of disposing of excess FAs. Thus, the HS process itself could
theoretically serve to decrease metabolic stress in the liver. Simi-
larly, increased VLDL secretion, increased ketone secretion, and
increased oxidative phosphorylation are all means through which
the liver can dispose of excess FAs.
Through systems level analysis in mice, we also observed that
glycine is the limiting substrate for the de novo synthesis of GSH
(Mardinoglu et al, 2015b). In a recent study comparing germ-free
and conventionally raised mice, we showed that the gut microbiota
alters the distribution of AAs along the gastrointestinal tract,
affecting the bioavailability of free AAs to the host (Mardinoglu
et al, 2015b). We also showed that microbiota-induced imbalances
in the utilization of AAs, particularly serine and glycine, may affect
the biological function of the host. Moreover, the presence of a gut
microbiota resulted in increased expression of Nnt in the liver,
adipose, and gastrointestinal tract tissues and a parallel decrease in
plasma and liver levels of glycine.
There is increasing interest in identifying patients at high risk of
developing NASH and, if possible, offering early treatment to
prevent the development of the disease. Our data indicate that
increased FA release from adipose tissue and decreased VLDL secre-
tion from the liver elevate the metabolic stress on the liver. There-
fore, it would potentially be of clinical value to take into account FA
release from adipose tissue together with the degree of HS in
subjects with HS.
Through personalized modeling of the subjects with varying
degree of HS, we observed that liver has capacity to clear the
◀ Figure 6. Supplementation of NAD+ and GSH precursors prevent NAFLD.Tenmice were given theWestern diet supplemented with NR (400 mg/kg/day) and serine (300 mg/kg/day) la gavage and NAC (1 g/l) in the drinking water, and tenmice were
only given the Western diet for 14 days.
A–E Hepatic lipids including (A) triglycerides (TG), (B) cholesterol esters (CE), (C) ceramides (CER), (D) sphingomyelin (SM), (E) phosphatidylethanolamine (PE) (normalized
to phosphatidylcholine (PC)) are shown in treated (cocktail supplemented) (n = 10), and control (n = 10) mice (mean  SEM).
F Quantification of amino acids from the liver of the same mice before and after supplementation (mean  SEM).
G Analysis of the molecular species of TGs extracted from the livers of the mice. Results from the control group are expressed as 100%, and results from the treated
group are expressed as % of the control group (mean  SEM).
H mRNA expression of the fatty acid synthase (Fasn) in the liver tissue of mice before and after the supplementation. Six subjects received one oral dose of L-serine
(200 mg/kg/day) for 14 days (mean  SEM).
I–L The human plasma (I) alanine aminotransferase (ALT), (J) aspartate aminotransferase (AST), (K) alkaline phosphatase (ALP), and (L) TGs levels are presented in each
human subject involved in the study before and after the supplementation with serine.
Data information: (A–G) *P < 0.05, **P < 0.01, ***P <0.001; Student’s t-test.
Source data are available online for this figure.
Table 3. Clinical characteristics of the six subjects involved in serine supplementation study.
Clinical variable Baseline (n = 6) After serine (n = 6) P-value
Liver fat (%) 26.8  6.0 20.4  7.0 <0.05
Age (years) 56.7  5.2 56.7  5.2 –
Weight (kg) 103.0  14.3 103.0  13.9 –
Body mass index (BMI) (kg/m²) 32.5  2.70 32.5  2.60 –
Alanine aminotransferase (ALT) (U/l) 50.8  15.2 37.6  5.3 <0.05
Aspartate aminotransferase (AST) (U/l) 34.5  8.10 27.4  8.4 <0.05
Alkaline phosphatase (ALP) (U/l) 76.3  17.2 71.3  17.9 <0.05
c-glutamyl transferase (GT) (U/l) 63.8  12.9 62.3  16.3 0.30
Fasting plasma glucose (mmol/l) 6.57  1.41 6.33  1.41 0.25
Fasting plasma insulin (FPI) (pmol/l) 46.3  33.8 34.7  25.2 0.23
HOMA-IR 2.15  1.85 1.54  1.49 0.18
LDL cholesterol (mmol/l) 3.68  0.80 3.85  0.94 0.50
HDL cholesterol (mmol/l) 1.00  0.21 1.02  0.18 0.30
Plasma triglycerides (TG) (mmol/l) 6.90  6.65 3.63  1.81 0.13
Total cholesterol (mmol/l) 6.23  1.49 5.85  1.15 0.18
Bilirubin (lmol/l) 7.33  4.11 6.48  3.94 0.13
Data are presented as means  SD. P-value (calculated using Student’s t-test) indicates the significance level of difference before and after the oral
supplementation of serine. Bold text indicate significantly different values.
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accumulated fatty acids by oxidizing them in the liver. Based on
our analysis, a three-step strategy including (i) increasing fatty
acid uptake into mitochondria, (ii) increasing the oxidation of the
fatty acids in the mitochondria, and (iii) increasing the availability
of GSH can be employed to treat the subjects with high HS (Fig 7).
A cocktail can be supplemented to boost these metabolic processes
to decrease the amount of hepatic lipids. L-carnitine and NR would
stimulate the transfer of fatty acids from cytosol to mitochondria
and boost the level of NAD+ which is required for mitochondrial
fatty acid oxidation. Impaired function of the electron transport
chain combined with increased rates of fatty acid oxidation may
lead to the accumulation of incomplete products of fatty acid
oxidation, which combined with increased levels of reactive
oxygen species, may contribute to insulin resistance (Loh et al,
2009). To avoid this, the level of GSH can be increased by
including serine and NAC into the content of the cocktail. This
three-step strategy may be useful to increase the level of fatty
acids oxidized in the liver, deal with the excess amount of oxygen
radicals resulted from increased fat oxidation, protect against free
radical-mediated oxidative stress, and eventually decrease HS in
NAFLD patients. Such cocktail can also be used for the treatment
of alcoholic fatty liver disease (AFLD) patients since HS is the
earliest abnormality in the pathogenesis of both AFLD and NAFLD
due to metabolic risk factors associated with insulin resistance
and/or metabolic syndrome in the presence or absence of alcohol
consumption (Lakshman et al, 2015). Considering that NAFLD and
T2D are common conditions that regularly coexist and can act
synergistically to drive adverse outcomes (Hazlehurst et al, 2016),
such cocktail can also be used in the treatment of the subjects
with T2D.
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Figure 7. Three-step strategy for the treatment of NAFLD and associated disorders.
Based on our results, we postulate a potential treatment strategy for NAFLD patients based on increased oxidation of fat and increased synthesis of GSH. A cocktail can
be supplemented to NAFLD patients to boost these metabolic processes and to decrease the hepatic lipid accumulation. NR can be supplemented to boost the oxidation
of the fat in the mitochondria by generating NAD+. Serine and NAC can be included in the cocktail to boost the level of GSH which is required for preventing the accumulation
of incomplete products of fatty acids oxidation. L-carnitine can also be added to the cocktail to boost the fatty acid uptake into mitochondria.
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In conclusion, we used personalized genome-scale metabolic
modeling to elucidate molecular mechanisms involved in the
progression of NAFLD and validated our predictions by generating
additional transcriptomics and metabolomics data. In addition, we
performed proof-of-concept studies in mice and human and showed
that supplementation of the precursors for NAD+ and GSH may be
useful in preventing and treatment of HS. Thus, personalized GEMs
provide a useful new tool for elucidating the underlying mecha-
nisms of disturbed liver metabolism in subjects with high HS and
proposed a strategy for treatment of NAFLD.
Materials and Methods
Subjects
We recruited 86 subjects with varying degrees of HS for studying
the response of liver to the HS. The clinical characteristics of the
subjects are presented in Table 1. We also collected liver tissue
samples from 12 morbidly obese subjects underwent bariatric
surgery and presented the subjects characteristics in Table 2. We
measured the mRNA expression of the identified target genes in
liver of obese and healthy subjects.
In order to show the effect of the serine on the treatment of
NAFLD, we recruited another six subjects and presented the
subjects characteristics in Table 3 before and after serine supple-
mentation. Each patient received one oral dose of ~20 g of L-serine
(200 mg/kg/day) for 14 days. Subjects included in our studies
met all the criteria for NAFLD including exclusion of other chronic
liver diseases such as viral hepatitis, risky alcohol consumption,
and metabolic disorders (e.g., hemochromatosis). The supplementa-
tion study has been submitted to https://ClinicalTrials.gov with the
identifier: NCT02599038.
Determination of liver, subcutaneous, and intra-abdominal fat
Magnetic resonance experiments were performed using three 1.5 T
clinical imagers (1× Sonata and 2× Avanto, Siemens, Erlangen,
Germany). Liver fat content was determined using proton magnetic
resonance spectroscopy, and subcutaneous abdominal and visceral
fat was measured by magnetic resonance imaging (Adiels et al,
2006; Lundbom et al, 2011).
Measurement of flux data
Lipoprotein fluxes were measured in fasted 73 subjects using stable
isotope infusion. After a bolus infusion of d3-leucine and d5-
glycerol, large (VLDL1) and small (VLDL2) VLDL subfractions were
isolated by ultracentrifugation and the enrichment of free leucine in
plasma, leucine in apoB, and glycerol in TG was measured using
gas chromatography–mass spectrometry (Adiels et al, 2005). Meta-
bolic fluxes were calculated using mathematical modeling as previ-
ously described (Adiels et al, 2005).
Muscle mass and fat mass calculations
The muscle mass of each subject was calculated from lean mass
using the previously described relationship (Clark et al, 2014) based
on their fat mass. A linear equation was fitted between BMI and fat
mass of the 44 subjects to predict the missing fat mass in the
remaining 29 subjects. The linear equation was defined as: fat mass
(kg) = 1.763 × BMI  26.75 (R2 = 0.69). Using this equation, fat
mass was calculated for the 29 subjects and the lean mass was then
calculated by subtracting the fat mass from the body weight of the
subjects. Finally, the muscle mass for each subject was calculated
based on the previously derived equation (Clark et al, 2014): muscle
mass = 0.63 × lean mass  4.1.
Inputs and outputs for the liver GEM in the fasting state
During fasting conditions, the liver takes up gluconeogenic
substrates and non-esterified FAs and AAs and produces blood
glucose (as an energy substrate for the brain), VLDL (as an energy
substrate for the rest of the body), ketone bodies, and plasma
proteins. The proteins secreted by the liver (mainly albumin) are
not necessarily a net loss for the liver since protein can be recycled.
However, in this study, the urea loss from urine was used as a proxy
for the net loss of protein from the liver.
The input variables in our model are thus: (i) AAs, (ii) lactate,
and (iii) FAs and glycerol. The output variables are as follows: (iv)
glucose derived from gluconeogenesis and glycogenolysis and (v)
ketone bodies as well as the measured VLDL secretion.
(i) AAs
In the fasting state, some AAs are released by muscle tissue.
Pozefsky et al (1976) experimentally quantified the AA release from
muscle tissue in the fasting state. They found that around 60% of all
the AAs released from muscle are glutamine and alanine, which are
the main substrates used for gluconeogenesis in the liver. These
experimentally measured values were incorporated into the model
based on the muscle mass of each subject.
Adipose tissue also releases AAs into the blood. Since the
subjects in the present study had varying degrees of adiposity, it is
important to know whether the release of AA differs between lean
and obese subjects. Patterson et al (2002) found that although AA
release is proportional to the amount of fat tissue a person has, it
also depends on blood flow, which decreases as the amount of fat
tissue increases. Thus, the release of AAs from adipose tissue is
independent of obesity. Therefore, we included in the model an
additional input of AAs based on adipose tissue mass. This contribu-
tion was calculated based on the study of Frayn and Karpe (Frayn &
Karpe, 2014) where they measured how much blood flows in and
out of adipose tissue (3–4 ml/min, 100 g fat tissue).
Another method (Ardilouze et al, 2004) provided information
on a person’s fat mass based on their BMI, gender, and age accord-
ing to the formula: body fat percent = (1.2 × BMI) + (0.23 × age) 
(10.8 × gender)  5.4, where gender is 0 for female and 1 for male
(Deurenberg et al, 1991). This resulted in an average body fat mass
of around 15 kg which gave an average blood flow of the whole
adipose tissue of around 31.5 l/h. Since Patterson et al (2002)
provided the values for the release of AAs based on body fat (in
lmol/l), the release of AAs by the adipose tissue (in mmol/h) was
calculated for each subject and used as an input to the personalized
models.
Muscle tissue and adipose tissue are not the only sources of AAs
for the liver during starvation. It has been shown that rat liver
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catabolizes around 25% of all intracellular proteins during the first
24 h of starvation (Cuervo & Dice, 1996). In our present analysis,
the total AAs released from muscle and adipose tissues do not seem
to satisfy the liver demand for AAs. During 16 h of fasting, the urea
excretion rate measured in humans was 392  44 mmol urea/24 h
(Norrelund et al, 2001). Assuming an average nitrogen content of
1.45 nitrogen atoms per AA and an average AA molar mass of
136.5 g/mol, the consumption of AAs in the liver after a 16-h fast
thus averaged close to 80 g/day (392 mmol/24 h × 136.5 g/mol/
1,000/1.45 = 77.6 g AAs/day). This value was almost constant after
40 h of fasting (440 mmol/24 h), indicating maintained (or even
increased) AA consumption in the fasting liver. The total amount of
AAs released by muscle and adipose tissues was calculated to be
close to 35 g/day indicating that the liver, in the present study,
likely catabolizes itself in relatively large quantities—approximately
40–45 g/day. The AA composition of human liver has been
measured by Benga and Ferdinand (Benga & Ferdinand, 1995). The
molar ratios of the AAs in liver were incorporated into an additional
input reaction to the model in order to achieve realistic AA net
consumption values.
(ii) Lactate
Lactate is used as a gluconeogenic substrate in the liver. Wallace
and Barritt (2005) claimed that the total amount of lactate produced
by red blood cells, the kidney, the medulla, and the retina is around
40 g/day assuming resting conditions. In addition, an extra 40 g is
produced by the rest of the body thus totaling around 80 g. This
corresponds to around 3.3 g/h = 37 mmol/h and was used as an
input to the model.
(iii) FAs and glycerol
Fatty acids are used by the liver for production of TG in VLDL. Glyc-
erol is a by-product of TG breakdown and subsequent FA release by
adipose tissue and can be used as a gluconeogenic substrate. The
FA and glycerol release from adipose tissue was estimated based on
a study by McQuaid et al (2011), and values of FA and glycerol
release from adipose tissue were retrieved for each subject in the
fasting state. This average value was around 30 lmol/min/kg fat
mass which is equal to 1.8 mmol/h/kg fat mass. Since the molar
ratio of glycerol release to FA release is 1:3, the glycerol release was
set as 0.6 mmol/h/kg fat mass. Both of these values were consid-
ered as upper bounds. However, Bickerton et al (2007) measured
the total FA influx into muscle in fasting subjects and found that
only around 4% of the FA released by adipose tissue was taken up
by muscle. Thus, the released FA of 1.8 mmol/h was used as an
input to the model.
(iv) Gluconeogenesis and glycogenolysis
Lactate, glutamine, alanine, and glycerol are the main gluco-
neogenic substrates. Another source of glucose is glycogen break-
down. McQuaid et al (2011) and Hellerstein et al (1997) reported
that under normal overnight fasting conditions, the contribution of
gluconeogenesis and glycogen breakdown to liver glucose output is
roughly equal. McQuaid et al (2011) also found that glycogen break-
down is approximately 5.5 lmol/kg/min in humans after an over-
night fast which corresponds to an average contribution from
glycogenolysis of around 5.7 g glucose/h for the subjects in our
study. The brain requires approximately 6 g glucose/h early in
fasting when ketone body production is still low (Bourre, 2006).
This suggests that during overnight fasting conditions, the total
glucose output from the liver is in the order of 10–15 g/h and it is
definitely higher than 6 g/h. In conclusion, an absolute minimum
contribution of gluconeogenesis to glucose output was set as
16.7 mmol/h (3 g/h).
(v) Ketone bodies
The total ketone body production in obese humans increases
dramatically up to around 60 mmol/h after 2–3 days of fasting and
up to around 75 mmol/h after 17–24 days of fasting (Reichard et al,
1974). However during an overnight fast, the glycogenolysis should
satisfy the majority of the brain’s energy demand and the ketone
body production rates for acetoacetate and beta-hydroxybutyrate
were therefore set at a lower bound of 0.1 mmol/h in the models.
Personalized genome-scale metabolic models for liver tissue
A functional GEM for hepatocytes in liver, iHepatocytes2322, was
reconstructed based on hepatocyte-specific proteomics data in
Human Protein Atlas (HPA, http://www.proteinatlas.org) (Uhlen
et al, 2015). Use of iHepatocytes2322 in conjunction with flux
balance analysis allowed for in silico metabolic simulation of liver
for each subject involved in our study. We incorporated the
measured/calculated uptake and secretion rate of the key metabo-
lites into each GEM and predicted the intracellular liver fluxes of
each patient. During the personalized simulation of liver tissue
GEMs, we allowed the uptake of oxygen, phosphate, minerals, etc.
(Dataset EV1) by the model and blocked the uptake of other
metabolites since we simulated the fasting state. After setting all the
bounds, we calculated the fluxes of all the subjects by minimizing
the sum of fluxes, based on the assumption that the cells will reduce
the pathway usage to a minimum for economic reasons (Dataset
EV2). To test the robustness of the result, we also calculated the
fluxes by random sampling without minimizing the flux sum and
observed the same key results (Datasets EV7–EV10).
To investigate the contribution of personalized inputs and
outputs (uptake of FAs and VLDL secretion) to our conclusions, we
performed a random control analysis (a random value with the
range of the maximum and minimum value of all the patients). We
found that when using random FA uptake or VLDL secretion alone
as an input or output to our personalized models, the correlation
between reactions carried by NNT and GSR and HS was significantly
decreased (Datasets EV11–EV14). Moreover, when both random FA
uptake and VLDL secretion were used, the correlation became non-
significant (Datasets EV15 and EV16). Thus, we concluded that both
personalized inputs and outputs are driving the conclusions reached
in our study.
Metabolomics data
Non-targeted metabolite detection and quantification was conducted
by the metabolomics provider Metabolon Inc. (Durham, USA) on
fasting plasma samples collected from the subjects with varying
degrees of HS. Samples were prepared using the automated
MicroLab STAR system from Hamilton Company. A recovery stan-
dard was added before the first step in the extraction process for
quality control purposes. To remove protein and dissociated small
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molecules bound to protein or trapped in the precipitated protein
matrix, and to recover chemically diverse metabolites, proteins were
precipitated with methanol under vigorous shaking for 2 min (Glen
Mills GenoGrinder 2000) followed by centrifugation. The resulting
extract was divided into four fractions: one for analysis by UPLC-
MS/MS with positive-ion mode electrospray ionization, one for
analysis by UPLC-MS/MS with negative-ion mode electrospray
ionization, one for analysis by GC-MS, and one sample reserved for
backup.
Following log transformation, with the minimum observed value
for each compound, Welch’s two-sample t-test was used to identify
the metabolites that differed significantly between subjects with
high and low HS. During the identification of the significant metabo-
lites as well as the significantly correlated metabolites, no data were
imputed for the missing values. The correlation analysis between
the metabolites was performed if both metabolites were detected in
at least 30 subjects involving in our study.
Mouse experiments
Twenty male C57BL/6J mice were fed a standard mouse chow diet
(Purina 7012, Harlan Teklad) and housed in a 12-h light–dark cycle.
From the age of 8 weeks, mice were fed a Western diet (TD.88137,
Harlan Laboratories, WI, USA) by separating into two groups. The
mice were then divided into two groups of 10 mice. One group of
mice was given the Western diet supplemented with NR (400 mg/
kg/day) and serine (300 mg/kg/day) la gavage and NAC (1 g/l) in
the drinking water for 14 days. The other group was only given the
Western diet for the 14 days.
The mice were housed at the University of Gothenburg animal
facility (Lab of Exp Biomed) and supervised by university veterinari-
ans and professional staff. The health status of our mice is
constantly monitored according to the rules established by the
Federation of European Laboratory Animal Science Associations.
The experiments were approved by the Gothenburg Ethical Commit-
tee on Animal Experiments.
Lipid extraction and analysis
Lipids were extracted as described previously (Lofgren et al, 2012).
Internal standards were added during the extraction. Lipids were
analyzed using a combination of HPLC and mass spectrometry as
described (Stahlman et al, 2013). Briefly, straight-phase HPLC was
used to purify ceramides (CER). Cholesteryl ester (CE), triacyl-
glycerol (TAG), phosphatidylethanolamine (PE), phosphatidylcholine
(PC), and sphingomyelin (SM) were quantified using a QTRAP 5500
mass spectrometer (Sciex, Concord, Canada) equipped with a robotic
nanoflow ion source, TriVersa NanoMate (Advion BioSciences, Ithaca,
NJ). CER were analyzed using reversed-phase HPLC coupled to a
triple-quadrupole Quattro Premier mass spectrometer (Waters,
Milford, MA, USA).
Data availability
Supplemental information is provided in Datasets EV1–EV16. The
accession number for the raw and processed RNA-seq data for liver
tissue reported in this paper is available at Gene Expression
Omnibus (GEO): GSE83322.
Expanded View for this article is available online.
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